Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: An immunocytochemical study

Modern Pathology

Volumn 21, Issue 5, 2008, Pages 626-631

  Ligato, Saverio ^a   Mandich, Daniza ^a   Cartun, Richard W ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Fine needle aspiration cytology; Glypican 3; Hepatocellular carcinoma; Immunocytochemistry; Liver

Indexed keywords

GLYPICAN;

ADENOMA; ANAPLASTIC CARCINOMA; ARTICLE; ASPIRATION BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LIVER CELL CARCINOMA; METASTASIS; NEUROENDOCRINE DISEASE; NODULAR HYPERPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

BIOPSY, FINE-NEEDLE; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 42549105933     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.26     Document Type: Article

References (11)

1. Wee A, Nilsson B, Tan LKA, et al. Fine needle aspiration biopsy of hepatocellular carcinoma: diagnostic dilemma at the ends of the spectrum. Acta Cytolol 1994;38:347-354.
2. Capurro M, Xiang Y, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Research 2005;65:6245-6254.
3. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598.
4. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
5. Filmus J, Capurro M. Glypican-3 and alpha-fetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 2004;8:207-212.
6. Man XB, Tang L, Zhang BH, et al. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int 2005;25:962-966.
7. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-564.
8. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Path 2006;30:1405-1411.
9. Wang YX, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Path 2006;37:1435-1441.
10. DiTommaso L, Franchi G, Park YN, et al. Diagnostic Value of HSP70, Glypican 3, and Glutamine Synthetase in Hepatocellular Nodules in Cirrhosis. Hepatology 2007;45:725-734.
11. Jia AY, Hwang YQ, Allegretta M, et al. Abstract #561 presented at the XXVI Congress of the IAP. Mod Path 2006;123.